Samsung C&T announced Tuesday that the company signed a memorandum of understanding with Flagship Pioneering, a US-based bio platform company, to expand its investment to foster biopharmaceutical innovation through the fund it jointly formed with Samsung Biologics. Since its launch in 2000, Flagship Pioneering has originated and fostered more than 100 scientific ventures, resulting in more than $70 billion in agg.